Phillip W. Kantoff

Phillip W. Kantoff

Top Cited Scholar 2023
Auto-generated profile, based on publicly available information

Phillip W. Kantoff

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PKPhilip W. Kantoff
Philip W. Kantoff
CHCelestia S. Higano
Celestia S. Higano
NSNeal D. Shore
Neal D. Shore
EBE. Roy Berger
E. Roy Berger
ESEric J. Small
Eric J. Small
PSPaul F. Schellhammer
Paul F. Schellhammer
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.

1 May 2015 in Cell
Verified
Journal Article
Closed access
DRDan Robinson
Dan Robinson
EAEliezer M. Van Allen
Eliezer M. Van Allen
YWYi-Mi Wu
Yi-Mi Wu
NSNikolaus Schultz
Nikolaus Schultz
RLRobert J. Lonigro
Robert J. Lonigro
ACArul M. Chinnaiyan
Arul M. Chinnaiyan

1 March 2002 in Cancer Cell
Verified
Journal Article
Closed access
DSDinesh Singh
Dinesh Singh
PFPhillip G. Febbo
Phillip G. Febbo
KRKenneth Ross
Kenneth Ross
DJDonald G. Jackson
Donald G. Jackson
JMJudith Manola
Judith Manola
WSWilliam R. Sellers
William R. Sellers

1 March 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HSHoward I. Scher
Howard I. Scher
Susan HalabiSusan Halabi
Susan Halabi
ITIan Tannock
Ian Tannock
MMMichael Morris
Michael Morris
CSCora N. Sternberg
Cora N. Sternberg
MHMaha Hussain
Maha Hussain
Purpose: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone.Methods: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data.Results: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur. Prostate cancers progressing despite castrate levels of testosterone are considered castration resistant and not hormone refractory. Eligibility is defined using standard disease assessments to authenticate disease progression, prior treatment, distinct clinical subtypes, and predictive models. Outcomes are reported independently for prostate-specific antigen (PSA), imaging, and clinical measures, avoiding grouped categorizations such as complete or partial response. In most trials, early changes in PSA and/or pain are not acted on without other evidence of disease progression, and treatment should be continued for at least 12 weeks to ensure adequate drug exposure. Bone scans are reported as “new lesions” or “no new lesions,” changes in soft-tissue disease assessed by RECIST, and pain using validated scales. Defining eligibility for prevent/delay end points requires attention to estimated event frequency and/or random assignment to a control group.Conclusion: PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.

20 April 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HSHowerd Scher
Howerd Scher
MMMichael J. Morris
Michael J. Morris
WSWalter M. Stadler
Walter M. Stadler
CHCelestia Higano
Celestia Higano
EBEthan Basch
Ethan Basch
AAAndrew J. Armstrong
Andrew J. Armstrong
Purpose: Evolving treatments, disease phenotypes, and biology, together with a changing drug development environment, have created the need to revise castration-resistant prostate cancer (CRPC) clinical trial recommendations to succeed those from prior Prostate Cancer Clinical Trials Working Groups. Methods: An international expert committee of prostate cancer clinical investigators (the Prostate Cancer Clinical Trials Working Group 3 [PCWG3]) was reconvened and expanded and met in 2012-2015 to formulate updated criteria on the basis of emerging trial data and validation studies of the Prostate Cancer Clinical Trials Working Group 2 recommendations. Results: PCWG3 recommends that baseline patient assessment include tumor histology, detailed records of prior systemic treatments and responses, and a detailed reporting of disease subtypes based on an anatomic pattern of metastatic spread. New recommendations for trial outcome measures include the time to event end point of symptomatic skeletal events, as well as time to first metastasis and time to progression for trials in the nonmetastatic CRPC state. PCWG3 introduces the concept of no longer clinically benefiting to underscore the distinction between first evidence of progression and the clinical need to terminate or change treatment, and the importance of documenting progression in existing lesions as distinct from the development of new lesions. Serial biologic profiling using tumor samples from biopsies, blood-based diagnostics, and/or imaging is also recommended to gain insight into mechanisms of resistance and to identify predictive biomarkers of sensitivity for use in prospective trials. Conclusion: PCWG3 moves drug development closer to unmet needs in clinical practice by focusing on disease manifestations most likely to affect prognosis adversely for therapeutics tested in both nonmetastatic and metastatic CRPC populations. Consultation with regulatory authorities is recommended if a trial is intended to seek support for drug approval.

4 August 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
CPColin C. Pritchard
Colin C. Pritchard
JMJoaquin Mateo
Joaquin Mateo
MWMichael F. Walsh
Michael F. Walsh
NSNavonil De Sarkar
Navonil De Sarkar
WAWassim Abida
Wassim Abida
PNPeter S. Nelson
Peter S. Nelson
Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established. We recruited 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis. We isolated germline DNA and used multiplex sequencing assays to assess mutations in 20 DNA-repair genes associated with autosomal dominant cancer-predisposition syndromes. A total of 84 germline DNA-repair gene mutations that were presumed to be deleterious were identified in 82 men (11.8%); mutations were found in 16 genes, including BRCA2 (37 men [5.3%]), ATM (11 [1.6%]), CHEK2 (10 [1.9% of 534 men with data]), BRCA1 (6 [0.9%]), RAD51D (3 [0.4%]), and PALB2 (3 [0.4%]). Mutation frequencies did not differ according to whether a family history of prostate cancer was present or according to age at diagnosis. Overall, the frequency of germline mutations in DNA-repair genes among men with metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer (P<0.001), including men with high-risk disease, and the prevalence of 2.7% in the Exome Aggregation Consortium, which includes 53,105 persons without a known cancer diagnosis (P<0.001). In our multicenter study, the incidence of germline mutations in genes mediating DNA-repair processes among men with metastatic prostate cancer was 11.8%, which was significantly higher than the incidence among men with localized prostate cancer. The frequencies of germline mutations in DNA-repair genes among men with metastatic disease did not differ significantly according to age at diagnosis or family history of prostate cancer. (Funded by Stand Up To Cancer and others.)